Molecular epidemiology: Carcinogen-DNA adducts and genetic susceptibility

Proceedings of the Society for Experimental Biology and Medicine

Volumn 216, Issue 2, 1997, Pages 172-180

  Warren, Amy J ^a   Shields, Peter G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARCINOGEN; DNA;

ARTICLE; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; DNA ADDUCT; ENVIRONMENTAL EXPOSURE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; RISK ASSESSMENT;

EID: 0030824593     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.3181/00379727-216-44167     Document Type: Article

References (119)

1. Western A, Harris CC. Chemical carcinogenesis. In: Holland JF, Bast RC Jr., Morton DL, Frei E III, Kufe DW, Weichselbaum RR, Eds. Cancer Medicine (4th ed). Baltimore, MD: Williams & Wilkins, Vol 2:pp261-276, 1997.
2. Yuspa SH, Shields PG. Etiology of cancer: Chemical. In: DeVita VT, Hellman S, Rosenberg SA, Eds. Cancer: Principles and Practice of Oncology (5th ed). Philadelphia: Lippincott-Raven, pp185-202, 1997.
3. Shields PG. Pharmacogenetics: Detecting sensitive populations. Environ Health Perspect 102(Suppl 11):81-87, 1994.
4. Perera FP. Molecular epidemiology: Insights into cancer susceptibility, risk assessment, and prevention. J Natl Cancer Inst 88:496-509, 1996.
5. Harris CC. Interindividual variation among humans in carcinogen metabolism, DNA adduct formation and DNA repair. Carcinogenesis 10:1563-1566, 1989.
6. Finkel AM. A Quantitative estimate of the variations in human susceptibility to cancer and its implications for risk management. In: Olin S, Farland W, Park C, Rhomberg L, Scheuplein R, Starr T, Wilson J, Eds. Low-Dose Extrapolation of Cancer. Washington, DC: ILSI Press, pp297-303, 1995.
7. Perera FP, Whyatt RM. Biomarkers and molecular epidemiology in mutation/cancer research. Mutat Res 313:117-129, 1994.
8. Hemminki K. DNA adducts in biomonitoring. J Occup Environ Med 37:44-49, 1995.
9. Poirier MC. Human exposure monitoring, dosimetry, and cancer risk assessment: the use of antisera specific for carcinogen-DNA adducts and carcinogen-modified DNA. Drug Metab Rev 26:87-109, 1994.
10. Santella RM, Yang XY, Hsieh LL, Young TL, Lu XQ, Stefanidis M, Perera FP. Immunologic methods for the detection of carcinogen adducts in humans. Basic Life Sci 53:33-44, 1990.
11. 32P-postlabeling methods for DNA adduct detection: Overview and critical evaluation. Drug Metab Rev 26:67-85, 1994.
12. Keith G, Dirheimer G. Postlabeling: a sensitive method for studying DNA adducts and their role in carcinogenesis. Curr Opin Biotechnol 6:3-11, 1995.
13. 35S]methionine: Analysis of DNA adducts of 4-aminobiphenyl. Proc Natl Acad Sci USA 91:1696-1700, 1994.
14. Sheabar FZ, Morningstar ML, Wogan GN. Peracylation of nucleosides with methionine: Foundation for a method to detect carcinogen adducts. Chem Res Toxicol 7:650-658, 1994.
15. Lay JO Jr., Chiarelli MP, Bryant MS, Nelson RW. Detection and characterization of DNA adducts at the femtomole level by desorption ionization mass spectrometry. Environ Health Perspect 99:191-193, 1993.
16. Fedtke N, Swenberg JA. Quantitative analysis of DNA adducts: The potential for mass spectrometric techniques. In: Groopman JD, Skipper PL, Eds. Molecular Dosimetry and Human Cancer: Analytical, Epidemiological, and Social Considerations. Boca Raton, FL: CRC Press, pp171-188, 1991.
17. Jeffrey AM. Application of fluorescence to analysis of genotoxicity. In: Groopman JD, Skipper PL, Eds. Molecular Dosimetry and Human Cancer: Analytical, Epidemiological and Social Considerations. Boca Raton, FL: CRC Press, pp249-261, 1991.
18. Weston A, Bowman ED, Manchester DK, Harris CC. Fluorescence detection of lesions in DNA. In: Sutherland BM, Woodhead AD, Eds. DNA Damage and Repair in Human Tissues. New York: Plenum Press, pp63-82, 1990.
19. 32P-postlabelling assay for carcinogen-DNA adduct determination. IARC Sci Publ Vol. 124. 243-254, 1993.
20. 6-alkylguanine in DNA by electrochemical detection. Mutat Res 307:61-66, 1994.
21. Tagesson C, Kallberg M, Klintenberg C, Starkhammar H. Determination of urinary 8-hydroxydeoxyguanosine by automated coupled-column high performance liquid chromatography: A powerful technique for assaying in vivo oxidative DNA damage in cancer patients. Eur J Cancer 31A:934-940, 1995.
22. Poirier MC, Reed E, Shamkhani H, Tarone RE, Gupta-Burt S. Platinum Drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy. Environ Health Perspect 99:149-154, 1993.
23. Weston A. Physical methods for the detection of carcinogen-DNA adducts in humans. Mutat Res 288:19-29, 1993.
24. Strickland PT, Routledge MN, Dipple A. Methodologies for measuring carcinogen adducts in humans. Cancer Epidemiol Biomarkers Prev 2:607-619, 1993.
25. Hemminki K, Grzybowska E, Chorazy M, Twardowska-Saucha K, Sroczynski JW, Putman KL, Randerath K, Phillips DH, Hewer A, Santella RM, Young TL, Perera FP. DNA adducts in humans environmentally exposed to aromatic compounds in an industrial area of Poland. Carcinogenesis 11:1229-1231, 1990.
26. Perera FP, Hemminki K, Gryzbowska E, Motkiewicz G, Michalska J, Santella RM, Young TL, Dickey C, Brandt-Rauf P, DeVivo I, Blaner W, Tsai WY, Chorazy M. Molecular and genetic damage in humans from environmental pollution in Poland. Nature 360:256-258, 1992.
27. Ovrebo S, Fjeldstad PE, Grzybowska E, Kure EH, Chorazy M, Haugen A. Biological monitoring of polycyclic aromatic hydrocarbon exposure in a highly polluted area of Poland. Environ Health Perspect 103:838-843, 1995.
28. Grzybowska E, Hemminki K, Chorazy M. Seasonal variations in levels of DNA adducts and X-spots in human populations living in different parts of Poland. Environ Health Perspect 99:77-81, 1993.
29. 32P-postlabeling assay. Carcinogenesis 14:545-550, 1993.
30. Weston A, Bowman ED, Shields PG, Trivers GE, Poirier MC, Santella RM, Manchester DK. Detection of polycyclic aromatic hydrocarbon-DNA adducts in human lung. Environ Health Perspect 99:257-259, 1993.
31. Manchester DK, Weston A, Choi JS, Trivers GE, Fennessey P, Quintana E. Detection of benzo[a]pyrene diol epoxide-DNA adducts in human placenta. Proc Natl Acad Sci USA 85:9243-9247, 1988.
32. Lewtas J, Mumford J, Everson RB, Hulka B, Wilcosky T, Kozimbo W, Thompson C, George M, Dobias L, Sram R, Li X, Gallagher J. Comparison of DNA adducts from exposure to complex mixtures in various human tissues and experimental systems. Environ Health Perspect 99:89-97, 1993.
33. Rothman N, Correa-Villasenor A, Ford DP, Poirier MC, Haas R, Hansen JA, O'Toole T, Strickland PT. Contribution of occupation and diet to white blood cell polycyclic aromatic hydrocarbon-DNA adducts in wildland firefighters. Cancer Epidemiol Biomarkers Prev 2:341-347, 1993.
34. Saxena R, Shaw GL, Relling MV, Frame JN, Moir DT, Evans WE, Caporaso N, Weiffenbach B. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum Mol Genet 3:923-926, 1994.
35. Wogan GN. Markers of exposure to carcinogens. Environ Health Perspect 81:9-17, 1989.
36. Harris CC, Vahakangas K, Newman MJ, Trivers GE, Shamsuddin AKM, Sinopoli NT, Mann DL, Wright WE. Detection of benzo[a-]pyrene diol epoxide-DNA adducts in peripheral blood lymphocytes and antibodies to the adducts in serum from coke oven workers. Proc Natl Acad Sci USA 82:6672-6676, 1985.
37. Perera FP, Hemminki K, Young TL, Brenner D, Kelly G, Santella RM. Detection of polycyclic aromatic hydrocarbon-DNA adducts in white blood cells of foundry workers. Cancer Res 48:2288-2291, 1988.
38. 32P-postlabelling of aromatic DNA adducts in white blood cells from iron foundry workers. Mutat Res 204:531-541, 1988.
39. 32P-postlabeling analysis of DNA from exfoliated oral mucosa cells as a means of monitoring exposure of the oral cavity to genotoxic agents. Carcinogenesis 10:1429-1434, 1989.
40. Van Schooten FJ, Van Leeuwen FE, Hillebrand MJ, de Rijke ME, Hart AA, van Veen HG, Oosterink S, Kriek E. Determination of benzo[a]pyrene diol epoxide-DNA adducts in white blood cell DNA from coke-oven workers: The impact of smoking. J Natl Cancer Inst 82:927-933, 1990.
41. Kang DH, Rothman N, Poirier MC, Greenberg A, Hsu CH, Schwartz BS, Baser ME, Groopman JD, Westen A, Strickland PT. Interindividual differences in the concentration of 1-hydroxypyrene-glucuronide in urine and polycyclic aromatic hydrocarbon-DNA adducts in peripheral white blood cells after charbroiled beef consumption. Carcinogenesis 16:1079-1085, 1995.
42. Rothman N, Poirier MC, Baser ME, Hansen JA, Gentile C, Bowman ED, Strickland PT. Formation of polycyclic aromatic hydrocarbon-DNA adducts in peripheral white blood cells during consumption of charcoal-broiled beef. Carcinogenesis 11:1241-1243, 1990.
43. Bryant MS, Vineis P, Skipper PL, Tannenbaum SR. Hemoglobin adducts of aromatic amines: Associations with smoking status and type of tobacco. Proc Natl Acad Sci USA 85:9788-9791, 988.
44. Leanderson P, Tagesson C. Cigarette smoke-induced DNA-damage: Role of hydroquinone and catechol in the formation of the oxidative DNA-adduct, 8-hydroxydeoxyguanosine. Chem Biol Interact 75:71-81, 1990.
45. Maclure M, Katz RB, Bryant MS, Skipper PL, Tannenbaum SR. Elevated blood levels of carcinogens in passive smokers. Am J Public Health 79:1381-1384, 1989.
46. Fielding JE, Phenow KJ. Health effects of involuntary smoking. N Engl J Med 319:1452-1460, 1988.
47. Wu-Williams AH, Samet JM. Environmental tobacco smoke: Exposure-response relationships in epidemiologic studies. Risk Anal 10:39-48, 1990.
48. Dunn BP, Vedal S, San RH, Kwan WF, Nelems B, Enarson DA, Stich HF. DNA adducts in bronchial biopsies. Int J Cancer 48:485-492, 1991.
49. 32P-postlabelling and aryl hydrocarbon hydroxylase activity in lung parenchyma of smokers and exsmokers. Carcinogenesis 12:1301-1305, 1991.
50. Phillips DH, Hewer A, Martin CN, Garner RC, King MM. Correlation of DNA adduct levels in human lung with cigarette smoking. Nature 336:790-792, 1988.
51. Cuzick J, Routledge MN, Jenkins D, Garner RC. DNA adducts in different tissues of smokers and non-smokers. Int J Cancer 45:673-678, 1990.
52. Phillips DH, She MN. DNA adducts in cervical tissue of smokers and non-smokers. Mutat Res 313:277-284, 1994.
53. Talaska G, al-Juburi AZ, Kadlubar FF. Smoking related carcinogen-DNA adducts in biopsy samples of human urinary bladder: Identification of N-(deoxyguanosin-8-yl)-4-aminobiphenyl as a major adduct. Proc Natl Acad Sci USA 88:5350-5354, 1991.
54. Perera FP, Estabrook A, Hewer A, Channing K, Rundle A, Mooney LA, Whyatt R, Phillips DH. Carcinogen-DNA adducts in human breast tissue. Cancer Epidemiol Biomarkers Prev 4:233-238, 1995.
55. Schoket B, Poirier MC, Vincze I. Biomonitoring of genotoxic exposure in aluminium plant workers by determination of DNA adducts in human peripheral blood lymphocytes. Sci Total Environ 163:153-163, 1995.
56. 32P-postlabeling analysis. Carcinogenesis 11:205-211, 1990.
57. Degawa M, Stem SJ, Martin MV, Guengerich FP, Fu PP, Ilett KF, Kaderlik RK, Kadlubar FF. Metabolic activation and carcinogen-DNA adduct detection in human larynx. Cancer Res 54:4915-4919, 1994.
58. Szyfter K, Hemminki K, Szyfter W, Szmeja Z, Banaszewski J, Yang K. Aromatic DNA adducts in larynx biopsies and leukocytes. Carcinogenesis 15:2195-2199, 1994.
59. Gallagher JE, Everson RB, Lewtas J, George M, Lucier GW. Comparison of DNA adduct levels in human placenta from polychlorinated biphenyl exposed women and smokers in which CYP 1A1 levels are similarly elevated. Teratog Carcinog Mutagen 14:183-192, 1994.
60. 32P-postlabeling procedure. Environ Health Perspect 99:229-231, 1993.
61. Foiles PG, Murphy SE, Peterson LA, Carmella SG, Hecht SS. DNA and hemoglobin adducts as markers of metabolic activation of tobacco-specific carcinogens. Cancer Res 52:2698S-2701S, 1992.
62. 6-methyldeoxyguanosine in esophageal DNA among individuals at high risk of esophageal cancer. Int J Cancer 36:661-665, 1985.
63. Harris CC, Mulvihill JJ, Thorgeirsson SS, Minna JD. Individual differences in cancer susceptibility. (clinical conference) Ann Intern Med 92:809-825, 1980.
64. Harris CC. Molecular epidemiology of human cancer in the 1990's. In: Gledhill BL, Mauro F, Eds. New Horizons in Biological Dosimetry. New York: Wiley-Liss, pp543-558, 1991.
65. Li FP. Familial cancer syndromes and clusters. Curr Probl Cancer 14:73-114, 1990.
66. Nebert DW. Role of genetics and drug metabolism in human cancer risk. Mutat Res 247:267-281, 1991.
67. Whyatt RM, Garte SJ, Cosma G, Bell DA, Jedrychowski W, Wahrendorf J, Randall MC, Cooper TB, Ottman R, Tang D, Tsai W-Y, Dickey DP, Manchester DK, Crofts F, Perera FP. CYP1A1 messenger RNA levels in placental tissue as a biomarker of environmental exposure. Cancer Epidemiol Biomarkers Prev 4:147-153, 1995.
68. McLemore TL, Adelberg S, Liu MC, McMahon NA, Yu SJ, Hubbard WC, Czerwinski M, Wood TG, Storeng R, Lubet RA, Eggleston JC, Boyd MR, Hines RN. Expression of CYP1A1 gene in patients with lung cancer: Evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst 82:1333-1339, 1990.
69. Kouri RE, McKinney CE, Slomiany DJ, Snodgrass DR, Wray NP, McLemore TL. Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryo-preserved lymphocytes. Cancer Res 42:5030-5037, 1982.
70. Rudiger HW, Nowak D, Hartmann K, Cerutti PA. Enhanced formation of benzo(a)pyrene:DNA adducts in monocytes of patients with a presumed predisposition to lung cancer. Cancer Res 45:5890-5894, 1985.
71. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS 263:131-133, 1990.
72. Hayashi S, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem (Tokyo) 110:407-111, 1991.
73. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol 14:77-87, 1993.
74. Crofts F, Taioli E, Trachman J, Cosma GN, Currie D, Toniolo P, Garte SJ. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 15:2961-2963, 1994.
75. Zhang ZY, Fasco MJ, Huang L, Guengerich FP, Kaminsky LS. Characterization of purified human recombinant cytochrome P450IA1-Ile462 and -Val462: Assessment of a role for the rare allele in carcinogenesis. Cancer Res 56:3926-3933, 1996.
76. Okada T, Kawashima K, Fukushi S, Minakuchi T, Nishimura S. Association between a cytochrome P450 CYPIA1 genotype and incidence of lung cancer. Pharmacogen 4:333-340, 1995.
77. Nakachi K, Imai K, Hayashi S, Watanabe J, Kawajiri K. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 51:5177-5180, 1991.
78. Tefre T, Ryberg D, Haugen A, Nebert DW, Skaug V, Brogger A, Borresen AL. Human CYP1A1 (cytochrome P1450) gene: Lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogen 1:20-25, 1991.
79. Shields PG, Caporaso NE, Falk RT, Sugimura H, Trivers GE, Trunp BF, Hoover RN, Weston A, Harris CC. Lung cancer, race, and a CYP1A1 genetic polymorphism. Cancer Epidemiol Biomarkers Prev 2:481-485, 1993.
80. Alexandrie A-K, Sundberg MI, Seidegard J, Tornling G, Rannug A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: A study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis 15:1785-1790, 1994.
81. Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, Anttila S, Vainio H. Point-mutational Msp1 and Ile-Val polymorphisms closely linked in the CYP1A1 gene: Lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev 1:485-189, 1992.
82. Hamada GS, Sugimura H, Suzuki I, Nagura K, Kiyokawa E, Iwase T, Tanaka M, Takahashi T, Watanabe S, Kino I. The heme-binding region polymorphism of cytochrome P450IA1 (CypIA1), rather than the RsaI polymorphism of IIE1 (CypIIE1), is associated with lung cancer in Rio de Janeiro. Cancer Epidemiol Biomarkers Prev 4:63-67, 1995.
83. Taioli E, Trachman J, Chen X, Toniolo P, Garte SJ. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res 55:3757-3758, 1995.
84. Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, Laughlin R, Nemoto T, Michalek AM, Harrington A, Ford TD, Shields PG. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res 55:3483-3485, 1995.
85. Badawi AF, Stern SJ, Lang NP, Kadlubar FF. Cytochrome P-450 and aceyltransferase expression as biomarkers of carcinogen-DNA adduct levels and human cancer susceptibility. In: Walker C, Groopman J, Slaga TJ, Klein-Szanto A, Eds. Genetics and Cancer Susceptibility: Implications for Risk Assessment. New York: Wiley-Liss, p109, 1996.
86. Cartwright RA, Glashan RW, Rogers JH, Ahmad RA, Barham-Hall D, Higgins E, Kahn MA. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: A pharmacogenetic epidemiological approach to bladder cancer. Lancet 2:842-845, 1982.
87. Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, Michalek AM, Laughlin R, Nemoto T, Gillenwater KA, Harrington AM, Shields PG. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. (see comments) JAMA 276:1494-1501, 1996.
88. Badawi AF, Hirvonen A, Bell DA, Lang NP, Kadlubar FF. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogenDNA adduct formation in the human urinary bladder. Cancer Res 55:5230-5237, 1995.
89. Weber WW, Vatsis KP. Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood. Pharmacogenetics 3:209-212, 1993.
90. Vatsis KP, Weber WW. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys 301:71-76, 1993.
91. Bell DA, Stephens EA, Castranio T, Umbach DM, Watson M, Deakin M, Elder J, Hendrickse C, Duncan H, Strange RC. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res 55:3537-3542, 1995.
92. Bell DA, Badawi AF, Lang NP, Ilett KF, Kadlubar FF, Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: Association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 55:5226-5229, 1995.
93. Jerina DM, Bend JA. Glutathione S-transferases. In: Jollow D, Kocsis JJ, Synder R, Vaino H, Eds. Biological Reactive Metabolites. New York: Plenum Press, p207, 1977.
94. Seidegard J, Vorachek WR, Pero RW, Pearson WR. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 85:7293-7297, 1988.
95. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: A common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 85:1159-1164, 1993.
96. Nakajima T, Elovaara E, Anttila S, Hirvonen A, Camus AM, Hayes JD, Ketterer B, Vainio H. Expression and polymorphism of glutathione S-transferase in human lungs: Risk factors in smoking-related lung cancer. Carcinogenesis 16:707-711, 1995.
97. Seidegard J, Pero RW, Markowitz MM, Roush G, Miller DG, Beattie EJ. Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: A follow up study. Carcinogenesis 11:33-36, 1990.
98. Nazar-Stewart V, Motulsky AG, Eaton DI, White E, Hornung SK, Leng ZT, Stapleton P, Weiss NS. The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma. Cancer Res 53:2313-2318, 1993.
99. Heckbert SR, Weiss NS, Hornung SK, Eaton DL, Motulsky AG. Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers. J Natl Cancer Inst 84:414-422, 1992.
100. Kato S, Bowman ED, Harrington AM, Blomeke B, Shields PG. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. J Natl Cancer Inst 87:902-907, 1995.
101. Wiencke JK, Kelsey KT, Lamela RA, Toscano WA Jr. Human glutathione S-transferase deficiency as a marker of susceptibility to epoxide-induced cytogenetic damage. Cancer Res 50:1585-1590, 1990.
102. van Poppel G, de Vogel N, van Balderen PJ, Kok FJ. Increased cytogenetic damage in smokers deficient in glutathione S-transferase isozyme mu. Carcinogenesis 13:303-305, 1992.
103. Bartsch H, Petruzzelli S, De Flora S, Hietanen E, Camus AM, Castegnaro M, Geneste O, Camoirano A, Saracci R, Giuntini C. Carcinogen metabolism and DNA adducts in human lung tissues as affected by tobacco smoking or metabolic phenotype: A case-control study on lung cancer patients. Mutat Res 250:103-114, 1991.
104. Zhong S, Howie AF, Ketterer B, Taylor J, Hayes JD, Beckett GJ, Wathen CG, Wolf CR, Spurr NK. Glutathione S-transferase mu locus: Use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis 12:1533-1537, 1991.
105. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Vainio H. The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis 14:1479-1481, 1993.
106. Brockmöller J, Kerb R, Drakoulis N, Nitz M, Roots I. Genotype and phenotype of glutathione S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls. Cancer Res 53:1004-1011, 1993.
107. London SJ, Daily AK, Cooper J, Navidi WC, Carpenter CL, Idle JR. Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles County, California. J Natl Cancer Inst 87:1246-1252, 1995.
108. Zhong S, Wyllie AH, Barnes D, Wolf CR, Spurr NK. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 14:1821-1824, 1993.
109. Bartsch H, Rojas M, Alexandrov K, Camus AM, Castegnaro M, Maelaveille C, Anttila S, Hirvonen K, Husgafvel-Pursiainen K, Hietanen E, Vainio H. Metabolic polymorphism affecting DNA binding and excretion of carcinogens in humans. Pharmacogenetics 5 Spec No:S84-S90, 1995.
110. Alexandrov K, Rojas M, Geneste O, Castagnaro M, Camus AM, Petruzzelli S, Giuntini C, Bartsch H. An improved fluorometric assay for dosimetry of benzo(a)pyrene diol-epoxide-DNA adducts in smokers' lung: comparisons with total bulky adducts and aryl hydrocarbon hydroxylase activity. Cancer Res 52:6248-6253, 1992.
111. Shields PG, Bowman ED, Harrington AM, Doan VT, Weston A. Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes. Cancer Res 53:3486-3492, 1993.
112. Anttila S, Vainio H, Hietanen E, Camus AM, Malaveille C, Brun G, Husgafvel-Pursiainen K, Heikkila L, Karjalainen A, Bartsch H. Immunohistochemical detection of pulmonary cytochrome P450IA and metabolic activities associated with P450IA1 and P450IA2 isozymes in lung cancer patients. Environ Health Perspect 98:179-182, 1992.
113. Tang D, Santella RM, Blackwood AM, Young TL, Mayer J, Jaretzki A, Grantham S, Tsai WY, Perera FP. A molecular epidemiological case-control study of lung cancer. Cancer Epidemiol Biomarkers Prev 4:341-346, 1995.
114. Hirvonen A, Nylund L, Kociba P, Husgafvel-Pursiainen K, Vainio H. Modulation of urinary mutagenicity by genetically determined carcinogen metabolism in smokers. (published erratum appears in Carcinogenesis 15:1767, 1994) Carcinogenesis 15:813-815, 1994.
115. Vineis P, Bartsch H, Caporaso N, Harrington AM, Kadlubar FF, Landi MT, Malaveille C, Shields PG, Skipper P, Talaska G, et al. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 369:154-156, 1994.
116. Yu MC, Skipper PL, Taghizadeh K, Tannenbaum SR, Chan KK, Henderson BE, Ross RK. Acetylator phenotype, aminobiphenylhemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. J Natl Cancer Inst 86:712-716, 1994.
117. Vineis P, Caporaso N, Tannenbaum SR, Skipper PL, Glogowski J, Bartsch H, Coda M, Talaska G, Kadlubar F. Acetylation phenotype, carcinogen-hemoglobin adducts, and cigarette smoking. Cancer Res 50:3002-3004, 1990.
118. Fodor SP, Read JL, Pirrung MC, Stryer L, Lu AT, Solas D. Light-directed, spatially addressable parallel chemical synthesis. Science 251:767-773, 1991.
119. Borman S. DNA chips of age: After period of gestation, technology for genetics analysis is blossoming. Chemical & Engineering News 74:42-43, 1997.